News
Curetis Reports Full-Year 2016 Financial Results and Updates 2017 Guidance
– Company strengthens commercial footprint in EMEA; expands installed base by 47%
– Acquisition of GEAR database and Gyronimo platform increase scale and scope of Unyvero offering
– Preparation for Unyvero market launch in the U.S.
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced financial results for the twelve months ended December 31, 2016, and provided further details on its outlook for 2017.
Company News: Curetis Expands Supervisory and Medical Advisory Boards
– Dr. Nils Clausnitzer nominated for election to Supervisory Board; Dr. Melissa Miller appointed to Medical Advisory Board
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that it has nominated Dr. med. Nils Clausnitzer, MBA, for election to its Supervisory Board. The election will take place at the upcoming General Shareholder Meeting on June 23, 2017. In addition, Dr. Melissa Miller has joined Curetis´ Medical Advisory Board (MAB).
Company News: Curetis to Present Data from Unyvero LRT U.S. FDA Clinical Trial at ASM Microbe
– U.S. data set complemented by recent clinical study data from European hospital
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis“), a developer of next-level molecular diagnostic solutions, today announced that significant clinical data updates on its Unyvero System and P55 / LRT cartridge for the diagnosis of pneumonia and lower respiratory tract infections will be presented at ASM Microbe 2017, being held June 1-5 in New Orleans, LA.
Company News: Curetis Starts Subsidiary Ares Genetics to Advance Genetic Antibiotic Resistance Testing
– Successful completion of GEAR asset and know how transfer from Siemens to Curetis
Curetis N.V. (the “Company” and, together with Curetis GmbH, “Curetis”), a developer of next-level molecular diagnostic solutions, today announced that the Company has established Ares Genetics GmbH, a wholly owned subsidiary of Curetis GmbH. Ares Genetics builds on GEAR GEnetic Antibiotic Resistance and Susceptibility Database and associated assets recently acquired for Siemens.